- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Dipalmitoylphosphatidylcholine.
Displaying page 1 of 1.
EudraCT Number: 2005-000489-37 | Sponsor Protocol Number: SURF-04-01 | Start Date*: 2005-08-26 |
Sponsor Name:Nektar Therapeutics | ||
Full Title: An open label, randomized, controlled study to evaluate the safety and efficacy of aerosolized surfactant, Curosurf®, delivered via nasal continuous positive airway pressure pulmonary drug delivery... | ||
Medical condition: The medical condition for this application is the Respiratory Distress Syndrome (RDS). RDS, also known as hyaline membrane disease, is characterized by lung immaturity and surfactant deficiency a... | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003519-40 | Sponsor Protocol Number: 03-CL-1202 | Start Date*: 2016-02-18 | |||||||||||||||||||||
Sponsor Name:Windtree Therapeutics, Inc | |||||||||||||||||||||||
Full Title: A MULTINATIONAL, MULTICENTER, MASKED, RANDOMIZED, CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF LUCINACTANT FOR INHALATION IN PRETERM NEONATES 26 TO 32 WEEKS GESTATIONAL AGE WITH RESPIRATOR... | |||||||||||||||||||||||
Medical condition: Respiratory Distress Syndrome (RDS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Completed) IE (Completed) NL (Completed) HU (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005624-26 | Sponsor Protocol Number: 03-CL-1401 | Start Date*: 2016-05-30 | |||||||||||||||||||||
Sponsor Name:Windtree Therapeutics, Inc. (formerly Discovery Laboratories, Inc.) | |||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 26 to 28 Weeks PMA. | |||||||||||||||||||||||
Medical condition: Respiratory Distress Syndrome (RDS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000106-32 | Sponsor Protocol Number: 03-CL-1702 | Start Date*: 2019-06-26 | |||||||||||||||||||||
Sponsor Name:Windtree Therapeutics, Inc. | |||||||||||||||||||||||
Full Title: A Multinational, Multicenter, Masked, Randomized, Parallel Group, Controlled Study to Assess the Safety and Efficacy of Lucinactant for Inhalation versus nCPAP alone in Preterm Neonates 26 to 32 We... | |||||||||||||||||||||||
Medical condition: Respiratory Distress Syndrome (RDS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
